In its first-quarter 2025 investor letter, Upslope Capital Management highlighted stocks such as Charles River Laboratories International, Inc. (NYSE:CRL). Charles River Laboratories International ...

Before the approval decision date, the FDA issued a complete response letter, CRL last month asking for at least one more clinical trial in relieving DED symptoms. No questions were raised on safety.

In trading on Tuesday, shares of Charles River Laboratories International Inc. (Symbol: CRL) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $105.18 ...